WWOX and Ewing sarcoma: Future large-scale, multi-institutional studies are warranted to validate RUNX2 as a prognostic marker, clarify the modulatory role of WWOX, and explore whether targeting this pathway can improve clinical outcomes in patients with Ewing sarcoma.